BRAF and melanoma: The first ones represent the main breakthrough in cancer immunotherapy, the latter (vemurafenib, dabrafenib, and encorafenib as BRAFi; trametinib, cobimetinib, and binimetinib as MEKi) are the standard of care of advanced melanoma carrying BRAF-V600 activating mutations.